U.S. Markets open in 2 hrs

OPKO Health, Inc. (OPK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.66+0.21 (+3.76%)
At close: 4:00PM EDT

5.70 +0.04 (0.80%)
Before hours: 7:10AM EDT

OPKO Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137
United States
305 575 4100
http://www.opko.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees6,096

Key Executives

NameTitlePayExercisedYear Born
Dr. Phillip FrostChairman & CEO971.2kN/A1936
Dr. Jane H. Hsiao M.B.A., Ph.D., MBAVice Chairman & Chief Technical Officer911.2kN/A1947
Mr. Adam E. LogalSr. VP & CFO611.2kN/A1978
Mr. Steven D. RubinExec. VP of Admin. & Director821.2k69.04k1960
Mr. Rulfo Fernando HernandezChief Accounting Officer, Treasurer & Global Corp. ControllerN/AN/A1979
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

Corporate Governance

OPKO Health, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 7. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.